Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer

Background Breast cancer (BC) is the most common malignancy among women. Nicotinamide (NAM) metabolism regulates the development of multiple tumors. Herein, we sought to develop a NAM metabolism-related signature (NMRS) to make predictions of survival, tumor microenvironment (TME) and treatment efficacy in BC patients. Methods Transcriptional profiles and clinical data from The Cancer Genome Atlas (TCGA) were analyzed. NAM metabolism-related genes (NMRGs) were retrieved from the Molecular Signatures Database. Consensus clustering was performed on the NMRGs and the differentially expressed genes between different clusters were identified. Univariate Cox, Lasso, and multivariate Cox regression analyses were sequentially conducted to develop the NAM metabolism-related signature (NMRS), which was then validated in the International Cancer Genome Consortium (ICGC) database and Gene Expression Omnibus (GEO) single-cell RNA-seq data. Further studies, such as gene set enrichment analysis (GSEA), ESTIMATE, CIBERSORT, SubMap, and Immunophenoscore (IPS) algorithm, cancer-immunity cycle (CIC), tumor mutation burden (TMB), and drug sensitivity were performed to assess the TME and treatment response. Results We identified a 6-gene NMRS that was significantly associated with BC prognosis as an independent indicator. We performed risk stratification according to the NMRS and the low-risk group showed preferable clinical outcomes (P < 0.001). A comprehensive nomogram was developed and showed excellent predictive value for prognosis. GSEA demonstrated that the low-risk group was predominantly enriched in immune-associated pathways, whereas the high-risk group was enriched in cancer-related pathways. The ESTIMATE and CIBERSORT algorithms revealed that the low-risk group had a higher abundance of anti-tumor immunocyte infiltration (P < 0.05). Results of Submap, IPS, CIC, TMB, and external immunotherapy cohort (iMvigor210) analyses showed that the low-risk group were indicative of better immunotherapy response (P < 0.05). Conclusions The novel signature offers a promising way to evaluate the prognosis and treatment efficacy in BC patients, which may facilitate clinical practice and management.

[1]  T. Fang,et al.  A novel lactate metabolism-related signature predicts prognosis and tumor immune microenvironment of breast cancer , 2022, Frontiers in Genetics.

[2]  Yi Zhou,et al.  Comprehensive analysis of pyroptotic gene prognostic signatures associated with tumor immune microenvironment and genomic mutation in breast cancer , 2022, Frontiers in Immunology.

[3]  Sheng Han,et al.  Construction and validation of an angiogenesis-related gene expression signature associated with clinical outcome and tumor immune microenvironment in glioma , 2022, Frontiers in Genetics.

[4]  Jin-hai Tang,et al.  Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer , 2022, Frontiers in Immunology.

[5]  Yi Yang,et al.  A Novel Five-Gene Signature Related to Clinical Outcome and Immune Microenvironment in Breast Cancer , 2022, Frontiers in Genetics.

[6]  W. Zhang,et al.  Improving ovarian cancer treatment decision using a novel risk predictive tool , 2022, Aging.

[7]  A. Bao,et al.  A Pyroptosis-Related Gene Signature Predicts Prognosis and Immune Microenvironment for Breast Cancer Based on Computational Biology Techniques , 2022, Frontiers in Genetics.

[8]  H. Ryu,et al.  Nicotinamide (niacin) supplement increases lipid metabolism and ROS‐induced energy disruption in triple‐negative breast cancer: potential for drug repositioning as an anti‐tumor agent , 2022, Molecular oncology.

[9]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[10]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[11]  Qianhui Xu,et al.  Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer , 2021, Frontiers in Immunology.

[12]  A. Schneeweiss,et al.  First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Mehta,et al.  Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer , 2021, Frontiers in Immunology.

[14]  C. Denkert,et al.  Breast cancer , 2021, The Lancet.

[15]  A. Vickers,et al.  Decision curve analysis to evaluate the clinical benefit of prediction models. , 2021, The spine journal : official journal of the North American Spine Society.

[16]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[17]  Daiying Zuo,et al.  The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. , 2021, European journal of pharmacology.

[18]  Pingping Shen,et al.  Targeting tumor-associated macrophages as an antitumor strategy. , 2020, Biochemical pharmacology.

[19]  Hongyang Wang,et al.  NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. , 2020, Cell metabolism.

[20]  P. Zhao,et al.  Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer , 2020, JAMA network open.

[21]  Yuqing Xiong,et al.  An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer , 2020, Theranostics.

[22]  Ameya R. Kirtane,et al.  Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma , 2020, Cancer Research.

[23]  M. Dore,et al.  The Elderly with Glucose-6-Phosphate Dehydrogenase Deficiency are More Susceptible to Cardiovascular Disease , 2020, Journal of atherosclerosis and thrombosis.

[24]  M. Moasser,et al.  Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer , 2020, Nature Communications.

[25]  J. Cuzick,et al.  Key steps for effective breast cancer prevention , 2020, Nature Reviews Cancer.

[26]  W. Poon,et al.  Impact of metformin on immunological markers: Implication in its anti-tumor mechanism. , 2020, Pharmacology & therapeutics.

[27]  A. Prat,et al.  Frequency and spectrum of PIK3CA somatic mutations in breast cancer , 2020, Breast Cancer Research.

[28]  S. Miyano,et al.  Landscape and function of multiple mutations within individual oncogenes , 2020, Nature.

[29]  Yibing Chen,et al.  Tumor-associated macrophages: an accomplice in solid tumor progression , 2019, Journal of Biomedical Science.

[30]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[31]  A. Sica,et al.  Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. , 2019, Cancer research.

[32]  Z. Cai,et al.  Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer , 2019, Nature Communications.

[33]  S. M. Toor,et al.  Immune checkpoint inhibitors: recent progress and potential biomarkers , 2018, Experimental & Molecular Medicine.

[34]  A. Butte,et al.  Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.

[35]  F. Su,et al.  Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages , 2018, Cell.

[36]  Zena Werb,et al.  Roles of the immune system in cancer: from tumor initiation to metastatic progression , 2018, Genes & development.

[37]  A. Munshi,et al.  Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies. , 2018, Current pharmaceutical design.

[38]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[39]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[40]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[41]  Yusuke Nakamura,et al.  Breast cancer: The translation of big genomic data to cancer precision medicine , 2017, Cancer science.

[42]  Lixia Zhu,et al.  Risk factors and clinical characteristics of non-promyelocytic acute myeloid leukemia of intracerebral hemorrhage: A single center study in China , 2017, Journal of Clinical Neuroscience.

[43]  L. Emens.  Breast Cancer Immunotherapy: Facts and Hopes , 2017, Clinical Cancer Research.

[44]  N. Harbeck,et al.  Breast cancer , 2017, The Lancet.

[45]  Lajos Pusztai,et al.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  L. V. van't Veer,et al.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.

[47]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[48]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[49]  E. Verdin.  NAD+ in aging, metabolism, and neurodegeneration , 2015, Science.

[50]  W. Kiess,et al.  Physiological and pathophysiological roles of NAMPT and NAD metabolism , 2015, Nature Reviews Endocrinology.

[51]  O. Peart.  Breast intervention and breast cancer treatment options. , 2015, Radiologic technology.

[52]  B. Sathian,et al.  The spectrum of genetic mutations in breast cancer. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[53]  A. Dueñas-González,et al.  Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin. , 2015, Oncology reports.

[54]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[56]  F M Blows,et al.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  R. S. Huang,et al.  Abstract 5561: Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines , 2014 .

[59]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[60]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[61]  D. Rossi,et al.  Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. , 2011, Cancer research.

[62]  E. Burgos,et al.  NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism. , 2011, Current medicinal chemistry.

[63]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[64]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[65]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[66]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[67]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[68]  Hemant Ishwaran,et al.  An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer , 2008, Proceedings of the National Academy of Sciences.

[69]  Jill P. Mesirov,et al.  GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..

[70]  Jill P. Mesirov,et al.  Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets , 2007, PloS one.

[71]  P. Hoskin,et al.  Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide , 2005, Cancer.

[72]  J. Kaanders,et al.  ARCON: experience in 215 patients with advanced head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.

[73]  Delin Chen,et al.  Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.

[74]  L. Arrighi,et al.  [Treatment of breast cancer]. , 1971, Prensa medica argentina.

[75]  Ash A. Alizadeh,et al.  SUPPLEMENTARY NOTE , 1879, Botanical Gazette.

[76]  I. Witz,et al.  The Tumor Microenvironment , 2012 .

[77]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[78]  S. Taysı,et al.  Elevated Serum Arginase Activity Levels in Patients with Breast Cancer , 2003, Surgery Today.

[79]  C. Meyer.  Survival Under Stress , 2002 .